evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

104 questions · 110 findings · 13 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 14 · 12.7%GRADE not reported 4 · 3.6%Very low 34 · 30.9%Low 25 · 22.7%Moderate 29 · 26.4%High 4 · 3.6%

Rituximab vs placebo

Common infections measured by clinical assessment over 28 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in common infections measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Cancer · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in cancer measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Mortality measured by clinical assessment over 12 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in mortality measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Disability worsening · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in disability worsening measured by EDSS over 24 months compared with placebo (moderate certainty).

1 finding from 1 review

Rituximab vs placebo

Clinical relapse · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in relapse measured by clinical assessment over 24 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Serious adverse events measured by clinical assessment over 12 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs intravenous methylprednisolone

CAS improvement (decrease) by 2 or more points · thyroid‐associated ophthalmopathy

Summary of findings table ‐ Rituximab showed no clear difference in CAS improvement (decrease) by 2 or more points compared with intravenous methylprednisolone (low certainty).

1 finding from 1 review

Rituximab vs placebo

Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Adverse effects · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes adverse effects compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs intravenous methylprednisolone

NOSPECS improvement (decrease) by 2 classes or more · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 or more classes compared with intravenous methylprednisolone (very low certainty).

1 finding from 1 review

Rituximab vs intravenous methylprednisolone

Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with intravenous methylprednisolone (very low certainty).

1 finding from 1 review

Rituximab vs intravenous methylprednisolone

Palpebral aperture improvement (decrease) by 3 mm or more · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes palpebral aperture improvement (decrease) by 3 mm or more compared with intravenous methylprednisolone (very low certainty).

1 finding from 1 review

Rituximab vs intravenous methylprednisolone

Motility improvement (increase) by 1 class or more · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes motility improvement (increase) by 1 class or more compared with intravenous methylprednisolone (very low certainty).

1 finding from 1 review